Compare EDAP & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EDAP | ALXO |
|---|---|---|
| Founded | 1979 | 2015 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.5M | 68.3M |
| IPO Year | 1997 | 2020 |
| Metric | EDAP | ALXO |
|---|---|---|
| Price | $3.73 | $1.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $8.50 | $3.30 |
| AVG Volume (30 Days) | 80.7K | ★ 186.5K |
| Earning Date | 11-06-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $74,853,925.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.67 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 0.61 | N/A |
| 52 Week Low | $1.21 | $0.40 |
| 52 Week High | $4.00 | $2.27 |
| Indicator | EDAP | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 68.40 | 52.43 |
| Support Level | $3.53 | $1.07 |
| Resistance Level | $3.45 | $1.18 |
| Average True Range (ATR) | 0.29 | 0.10 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 76.92 | 60.87 |
Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.